ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022

Posted: April 19, 2022 at 1:53 am

WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidney disease (CKD), preventing end-stage renal disease (ESRD), and preventing the need for dialysis. Social Capital Suvretta Holdings Corp. III (SCS) (Nasdaq: DNAC), is a special purpose acquisition company. ProKidney and SCS today announced that they will host an analyst and investor day in New York on Thursday, April 28, 2022, beginning at 8:00 a.m. ET.

Read the original:
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022

Related Posts